Titlebook: Kala Azar in South Asia; Current Status and C T.K. Jha,E. Noiri Book Jan 20111st edition Springer Science+Business Media B.V. 2011 Biomarke

夸張

GLIB

Epidemiology of Drug-Resistant Kala-Azar in India and Neighboring Countriest 98.2% until the late 1980s. However, by the 1990s longer treatment was required, and the efficacy rate declined while the incidence of serious toxicities increased. Thus, the use of this drug was discontinued. Among the drugs administered orally, miltefosine was found highly effective in the treat

Ambulatory

anniversary

Combination Therapy for Leishmaniaseseffects and can cure more than 95% of VL patients with a single infusion, but it is very expensive. Hence, the Drugs for Neglected Diseases initiative (Geneva, Switzerland) in collaboration with the Indian Medical Research Council (Rajendra Memorial Research Institute, Patna, India) and the Kala-Aza

無(wú)目標(biāo)

Challenges in the Diagnosis of Visceral Leishmaniasis on the Indian Subcontinentshown excellent performance on the Indian subcontinent, but the latter is preferred, as it is simpler to use. The proper implementation of these diagnostic strategies within the VL elimination program involves not only the procurement, training, and supervision of staff, but also quality control bot

Tdd526

The Potential of Urinary Tests in the Management of Kala-Azarinvaluable as a triage tool and for monitoring the severity of the disease. In addition, we discuss the potential usefulness of urinary interleukin-18, a biomarker for acute kidney injury, in monitoring kala-azar activity. Further studies of this and other recently discovered urinary biomarkers are

壟斷

Post-kala-azar Dermal Leishmaniasis: Facing the Challenge of Eliminating Kala-Azar from South Asiams in India, Nepal, and Bangladesh. Control and research efforts are urgently needed to improve PKDL surveillance and case management in order to reduce delays in diagnosis and treatment and, hence, reduce morbidity and the risk of transmission.

斗爭(zhēng)

Climate Change and Kala-Azarakdown of sanitation systems, increased salinity, more vector growth, and more water- and food-borne diseases, which ultimately impact human health. Environmental changes often modify the transmission patterns of vector-borne diseases. Increases in temperature due to climate change provide a better

比喻好

The Role of Policy Makers in Achieving the Target for Kala-Azar Elimination in South Asia: The Banglapid diagnostic test for diagnosis combined with the use of the oral drug miltefosine. A phase 4 trial on miltefosine was conducted by the Ministry of Health in Bangladesh, and miltefosine was introduced for the treatment of kala-azar in 2007, but the drug disappeared from the market the following m

Anonymous